唑来膦酸联合递增剂量白介素-2在单倍体造血干细胞移植后早期体内生成Vγ9Vδ2 T细胞的I期研究
这项单中心、开放标签、剂量递增I期研究(NCT03862833)评估单倍体造血干细胞移植后早期使用唑来膦酸联合递增低剂量白介素-2生成Vγ9Vδ2 T细胞的安全性与可行性。2019年4月至2022年9月共纳入26例患者,其中16例最终接受治疗、7例为仅接受移植的对照。三个剂量水平下剂量限制性毒性分别为1、0、1例,未达到最大耐受剂量;白介素-2治疗期间Vγ9Vδ2 T细胞数显著高于对照。
要点
- 单倍体移植后早期联合唑来膦酸与低剂量白介素-2可在体内生成Vγ9Vδ2 T细胞。
- 三个剂量水平剂量限制性毒性分别为1、0、1例,最大耐受剂量未达到。
- 白介素-2治疗期间Vγ9Vδ2 T细胞数显著高于仅接受移植的对照。
核心结论
- 单倍体造血干细胞移植后早期通过唑来膦酸联合重复白介素-2输注在体内生成Vγ9Vδ2 T细胞是可行的。
- 本研究为未来开展2期研究铺路,以期记录这种过继免疫治疗减少移植后复发。
研究设计与样本
- 单中心、开放标签、剂量递增I期研究(ClinicalTrials.gov:NCT03862833),采用标准3+3方案确定最大耐受剂量。
- 2019年4月至2022年9月共纳入26例患者,其中16例最终接受治疗,7例为仅接受单倍体造血干细胞移植的对照。
- 白介素-2递增低剂量为每周5天、共4周,联合单次剂量唑来膦酸,两者均从移植后第+15天后的第一个周一开始。
- 通过多参数流式细胞术监测血样本中Vγ9Vδ2 T细胞,并与单倍体移植受者对照队列比较。
主要发现
- 三个测试剂量水平的剂量限制性毒性分别为1、0、1例,最大耐受剂量未达到。
- 白介素-2治疗期间Vγ9Vδ2 T细胞数显著高于对照。
- 单倍体造血干细胞移植后供者Vγ9Vδ2 T细胞的存在与无病生存改善相关。
- 这些细胞以非MHC限制方式杀伤肿瘤细胞,不诱导移植物抗宿主病,并可通过唑来膦酸联合白介素-2刺激生成。
临床怎么用
- 作者认为单倍体移植后早期使用唑来膦酸联合重复白介素-2输注在体内生成Vγ9Vδ2 T细胞是可行的。
- 作者提出本研究为未来开展2期研究铺路,以期记录这种过继免疫治疗减少移植后复发。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The presence of donor Vγ9Vδ2 T-cells after haploidentical hematopoietic stem cell transplant (h-HSCT) has been associated with improved disease-free survival. These cells kill tumor cells in a non-MHC restricted manner, do not induce graft-versus-host disease (GVHD), and can be generated by stimulation with zoledronic acid (ZA) in combination with interleukin-2 (IL-2). This monocentric phase I, open-label, dose-escalating study (ClinicalTrials.gov: NCT03862833) aimed at evaluating the safety and possibility to generate Vγ9Vδ2 T-cells early after h-HSCT. It applied a standard 3 + 3 protocol to determine the maximum tolerated dose (MTD) of increasing low-doses of IL-2 (5 days [d] per week, 4 weeks) in combination with a single dose of ZA, starting both the first Monday after d + 15 posttransplant. Vγ9Vδ2 T-cell monitoring was performed by multiparameter flow cytometry on blood samples and compared with a control cohort of h-HSCT recipients. Twenty-six patients were included between April 2019 and September 2022, 16 of whom being ultimately treated and seven being controls who received h-HSCT only. At the three dose levels tested, 1, 0, and 1 dose-limiting toxicities were observed. MTD was not reached. A significantly higher number of Vγ9Vδ2 T-cells was observed during IL-2 treatment compared with controls. In conclusion, early in vivo generation of Vγ9Vδ2 T-cells is feasible after h-HSCT by using a combination of ZA and repeated IL-2 infusions. This study paves the way to a future phase 2 study, with the hope to document lesser posttransplant relapse with this particular adaptive immunotherapy.
引用
- Jullien M, Guillaume T, Le Bourgeois A, et al. Phase I study of zoledronic acid combined with escalated doses of interleukine-2 for early in vivo generation of Vγ9Vδ2 T-cells after haploidentical stem cell transplant with posttransplant cyclophosphamide. Am J Hematol. 2024. PMID: 38165016. doi:10.1002/ajh.27191
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。